ÂÜÀòÂÒÂ×

Elisabeth Kogan has a diverse work experience in the biotech and pharmaceutical industries. Elisabeth co-founded Clexio Biosciences in 2018 and currently serves as the CEO. Prior to this, they worked at Teva Pharmaceuticals for many years, holding various high-level positions such as SVP InnoTech (Innovation & Technologies) from 2016 to 2018, SVP Global Generic R&D from 2010 to 2015, and VP Global Portfolio Strategy from 2009 to 2010. Elisabeth was also a Board Member at École Polytechnique from 2013 to 2018. Before joining Teva, they worked at Teva Pharmaceuticals as the VP Sales & Marketing - TAPI from 2002 to 2008. Elisabeth began their career in the pharmaceutical industry at sanofi-aventis in 1996, where they worked in process development.

Elisabeth Kogan obtained their MA in Sciences and Business from CentraleSupélec from 1993 to 1996. Prior to that, they attended classes préparatoires Chaptal from 1991 to 1993, where they studied mathematics, physics, and chemistry.